Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

TY - JOUR

T1 - Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

AU - Tefferi, Ayalew

AU - Cervantes, Francisco

AU - Mesa, Ruben

AU - Passamonti, Francesco

AU - Verstovsek, Srdan

AU - Vannucchi, Alessandro M

AU - Gotlib, Jason

AU - Dupriez, Brigitte

AU - Pardanani, Animesh

AU - Harrison, Claire

AU - Hoffman, Ronald

AU - Gisslinger, Heinz

AU - Kröger, Nicolaus

AU - Thiele, Juergen

AU - Barbui, Tiziano

AU - Barosi, Giovanni

PY - 2013/8/22

Y1 - 2013/8/22

N2 - The current document is a revision of the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for treatment response in myelofibrosis (MF) and represents a collaborative effort by the IWG-MRT and the European LeukemiaNet to objectively assess the value of new drugs in inducing morphologic remission or improvement in MF-associated symptomatic burden (MF-SB). Some of the changes in the current revision include stricter definitions of red cell transfusion dependency and independency and consideration of the Myeloproliferative Neoplasm Symptom Assessment Form as a tool to quantify meaningful changes in disease-related symptoms. Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-SB were annotated as clinical improvement, anemia response, spleen response, or symptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The document also includes recommendations for assessing cytogenetic and molecular remissions, without mandating their inclusion for CR assignment.

AB - The current document is a revision of the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for treatment response in myelofibrosis (MF) and represents a collaborative effort by the IWG-MRT and the European LeukemiaNet to objectively assess the value of new drugs in inducing morphologic remission or improvement in MF-associated symptomatic burden (MF-SB). Some of the changes in the current revision include stricter definitions of red cell transfusion dependency and independency and consideration of the Myeloproliferative Neoplasm Symptom Assessment Form as a tool to quantify meaningful changes in disease-related symptoms. Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-SB were annotated as clinical improvement, anemia response, spleen response, or symptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The document also includes recommendations for assessing cytogenetic and molecular remissions, without mandating their inclusion for CR assignment.

KW - Bone Marrow Neoplasms

KW - Chronic Disease

KW - Consensus

KW - Disease Progression

KW - Erythrocyte Transfusion

KW - Europe

KW - Humans

KW - International Cooperation

KW - Medical Oncology

KW - Myeloproliferative Disorders

KW - Practice Guidelines as Topic

KW - Primary Myelofibrosis

KW - Remission Induction

KW - Treatment Outcome

U2 - 10.1182/blood-2013-03-488098

DO - 10.1182/blood-2013-03-488098

M3 - SCORING: Journal article

C2 - 23838352

VL - 122

SP - 1395

EP - 1398

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 8

ER -